Inclusion Criteria : 
  -  Patients who are day -  10 pre - to day +  30 post - allogeneic hematopoietic cell transplant ( AHCT ) from any donor or graft source and for any conditioning regimen
  -  Patients who have received treatment with meropenem or piperacillin - tazobactam ( pip - tazo ) intravenously ( IV ) ( of at least  24 hours duration ) in past  7 days
  -  Controlled infection defined as hemodynamically stable and not requiring supplemental oxygen of more than  2 liters via nasal cannula
  -  Patients who are able to take oral medications in suspension form
  -  Patients who are able to provide informed consent ( IC ) and comply with all study visits and procedures
Exclusion Criteria : 
  -  Patients who are anticipated to require continued broad spectrum antibiotics with meropenem or pip - tazo IV for >  96 hours post - engraftment such as for known , documented infections necessitating prolonged treatment
  -  Patients with a prior documented infection with mycormycetes
  -  Patients who are greater than  2 days from time of neutrophil engraftment post AHCT
  -  Patients with active enteric infections
  -  Patients with acute GVHD >  = grade II
  -  Patients unwilling or unable to undergo the FMT via retention enema procedure
  -  Patients who have received treatment with an investigational agent within  2 weeks of enrollment
  -  Patients unable to tolerate oral decontamination regimen of pip - tazo and nystatin due to prior allergy or intolerance of these medications
  -  Patients with any medical or psychological condition that , in the opinion of the investigator , might interfere with the subject's participation in the trial , pose any additional risk for the subject , or confound the assessments of the subject